Neuroblastoma Clinical Trial
Official title:
Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma
Well-regulated glycosylation is essential for the normal development of the nervous system.
Altered expression of glycosyltransferases with resulting dysregulated glycosylation of
neuroblastic cells might lead to the development of NB. The
β1,4-N-acetylgalactosaminyltransferase III (B4GALNT3) exhibits GalNAc transferase activity
to form the GalNAcβ1,4GlcNAc (LacdiNAc or LDN) structure. The Drosophila B4GALNTA, homolog
of human B4GALNT3, has been suggested to regulate the neuronal development. By
immunohistochemical studies, we demonstrated that the expression of B4GALNT3 correlated well
with histological grade of differentiation in NB tumor samples. Since well differentiated
tumors usually carry a better prognosis, we thus speculate that expression of B4GALNT3 in
tumor tissues can a favorable prognostic factor of NB.
To explore the role of B4GALNT3 in the prognosis of NB, we propose the following project
with two specific aims:
Aim Ⅰ: Establishing the significance of B4GALNT3 in the prognosis of NB: We plan to collect
90 NB tumor samples, and evaluate the RNA and protein expression levels by Q-PCR, Western
blot, and immunohistochemistry in the tumor samples. The results will be compared with the
other clinicopathological and biological factors of NB. Also the expression levels of
B4GALNT3 in tumor tissues will be correlated to the patients' outcome to clarify whether
B4GALNT3 could be a prognosis marker of NB.
Aim II: Clarifying the effects of B4GALNT3 on NB cell behavior in vitro and in vivo. For
further strengthening the prognostic role of B4GALNT3 in NB, NB cell phenotype and behavior
changes after overexpression or knock-down of B4GALNT3 are evaluated by in vitro assays as
well as by a nude mice xenograft model.
In summary, if our project can establish the role of B4GALNT3 expression in NB, we may
further subclassify the NB patients, and give the NB patients more appropriate therapies to
improve patients' outcome. Furthermore, B4GALNT3 could potentially serves as a therapeutic
target in the future.
n/a
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00492167 -
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
|
Phase 1 | |
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03107988 -
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
|
Phase 1 | |
| Recruiting |
NCT04253015 -
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
|
||
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
| Recruiting |
NCT02933333 -
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
|
Phase 4 | |
| Recruiting |
NCT00588068 -
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
|
||
| Recruiting |
NCT04301843 -
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
|
Phase 2 | |
| Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
| Recruiting |
NCT04040088 -
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
|
Early Phase 1 | |
| Recruiting |
NCT06057948 -
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
|
Phase 2 | |
| Not yet recruiting |
NCT06335745 -
PediCARE Health Equity Intervention in High-Risk Neuroblastoma
|
N/A | |
| Recruiting |
NCT02559778 -
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
|
Phase 2 | |
| Completed |
NCT02441062 -
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT02245997 -
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
|
N/A | |
| Not yet recruiting |
NCT01156350 -
Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT01192555 -
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01222780 -
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
|
Phase 1 |